ERBB2 and non-small cell lung carcinoma: Taken together, these results demonstrate that the engineered destabilized 3’UTR ARE of ERBB2 targeted, destabilized, and degraded the ERBB2 transcript and protein expression and induced increased apoptosis and reduced migration and outperformed trastuzumab in the NCI-H1975 model of the deadly EGFR T790M non-small-cell lung cancer.